Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study.

Perkovic V, Ninomiya T, Arima H, Gallagher M, Jardine M, Cass A, Neal B, Macmahon S, Chalmers J.

J Am Soc Nephrol. 2007 Oct;18(10):2766-72. Epub 2007 Sep 5.

2.
3.

Making PROGRESS in stable patients post stroke or transient ischaemic attack: implications for general practice.

Jackson G.

Int J Clin Pract. 2003 Jun;57(5):385-7. Review. Erratum in: Int J Clin Pract. 2003 Jul-Aug;57(6):534.

PMID:
12846342
4.

A review of Perindopril in the reduction of cardiovascular events.

Campbell DJ.

Vasc Health Risk Manag. 2006;2(2):117-24. Review.

5.

Efficacy and safety of fixed combination of perindopril and indapamide in type 2 diabetes: results from ADVANCE in context of available evidence.

Chalmers J, Joshi R, Kengne AP, Ninomiya T, Bi Y, Bompoint S, Billot L, Patel A; ADVANCE Collaborative Group.

J Hypertens Suppl. 2008 Sep;26(3):S21-7. Review.

PMID:
19363849
6.

Specific properties and effect of perindopril in controlling the renin-angiotensin system.

Ferrari R, Pasanisi G, Notarstefano P, Campo G, Gardini E, Ceconi C.

Am J Hypertens. 2005 Sep;18(9 Pt 2):142S-154S. Review.

PMID:
16125051
7.

Evidence for benefits of perindopril in hypertension and its complications.

Laurent S.

Am J Hypertens. 2005 Sep;18(9 Pt 2):155S-162S. Review.

PMID:
16125052
8.

Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease.

Brugts JJ, Ferrari R, Simoons ML.

Expert Rev Cardiovasc Ther. 2009 Apr;7(4):345-60. doi: 10.1586/erc.09.2. Review. Erratum in: Expert Rev Cardiovasc Ther. 2009 Jun;7(6):722.

PMID:
19379059
9.

Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril.

Ferrari R.

Expert Rev Cardiovasc Ther. 2005 Jan;3(1):15-29. Review.

PMID:
15723572
10.

PROGRESS: Prevention of Recurrent Stroke.

Arima H, Chalmers J.

J Clin Hypertens (Greenwich). 2011 Sep;13(9):693-702. doi: 10.1111/j.1751-7176.2011.00530.x. Epub 2011 Sep 2. Review.

11.

Perindopril: a review of its use in patients with or at risk of developing coronary artery disease.

Curran MP, McCormack PL, Simpson D.

Drugs. 2006;66(2):235-55. Review.

PMID:
16451098
12.

[Which optimal antihypertensive bitherapy for kidney patients?].

Bonne JF, Shahapuni I, Mailliez S, Oprisiu R, Temmar M, Choukroun G, Massy ZA, Fournier A.

Nephrol Ther. 2007 Jun;3(3):79-88. Epub 2007 May 8. Review. French.

PMID:
17540309
15.

Antihypertensive treatment and stroke prevention in patients with and without chronic kidney disease: a review of controlled trials.

Segall L, Oprisiu R, Fournier A, Covic A.

J Nephrol. 2008 May-Jun;21(3):374-83. Review.

PMID:
18587726
16.

Achievement of target blood pressure levels in chronic kidney disease: a salty question?

De Nicola L, Minutolo R, Bellizzi V, Zoccali C, Cianciaruso B, Andreucci VE, Fuiano G, Conte G; investigators of the TArget Blood Pressure LEvels in Chronic Kidney Disease (TABLE in CKD) Study Group.

Am J Kidney Dis. 2004 May;43(5):782-95. Review.

PMID:
15112168
17.

Atorvastatin: its clinical role in cerebrovascular prevention.

Gaspardone A, Arca M.

Drugs. 2007;67 Suppl 1:55-62. Review.

PMID:
17910521
18.

Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin.

Bybee KA, Lee JH, O'Keefe JH.

Curr Med Res Opin. 2008 Apr;24(4):1217-29. doi: 10.1185/030079908X292001 . Epub 2008 Mar 20. Review.

PMID:
18358084
19.

Perindopril.

Alfakih K, Hall AS.

Expert Opin Pharmacother. 2006 Jan;7(1):63-71. Review.

PMID:
16370923
20.

Implications of the ADVANCE study for clinical practice.

Zannad F.

J Hypertens Suppl. 2008 Sep;26(3):S29-32. Review.

PMID:
19363850

Supplemental Content

Support Center